Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_assertion type Assertion NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_head.
- NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_assertion description "[Since IL-1 and TNF-alpha are related to inflammation and their immunoexpression increases in PC, inhibition of these cytokines might be a possible target for PC treatment, because they decrease the activity of all transduction pathway members that activate transcription factors such as NF-kappaB, Elk-1 or ATF-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_provenance.
- NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_assertion evidence source_evidence_literature NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_provenance.
- NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_assertion SIO_000772 18752500 NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_provenance.
- NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_assertion wasDerivedFrom befree-2016 NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_provenance.
- NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_assertion wasGeneratedBy ECO_0000203 NP690076.RAlX0NdMvIh3gKuoVBcpTs6epcQywrkvRHilrGMiFAsPY130_provenance.